Highlights
- Third quarter 2026 Revenue was $325,624 thousand, compared with $268,651 thousand, and Net Income was $31,025 thousand.
- The 10-Q describes a June 2026 Cybersecurity incident involving unauthorized Acquisition of source code copies and four inactive data files.
- On the call, management raised its 2026 adjusted EBITDA outlook to $543 million to $549 million.
- Waystar repurchased 889,222 shares in the third quarter under its $200 million authorization announced May 19, 2026.
Waystar Holding Corp. (NASDAQ:WAY) shares were trading at USD 28.16 on November 17, 2026, up 0.18%, with a relative Volume at time of 2.11. The healthcare payments software company announced a $200 million share repurchase plan on May 19, identified a cybersecurity incident in early June and, on November 2, filed its third quarter 2026 Form 10-Q and updated its full-year outlook.
Waystar is a Delaware corporation headquartered in Lehi, Utah. It provides healthcare organizations with AI-powered software that simplifies healthcare payments for providers, through provider solutions and patient payments solutions. The company says it serves over 30,000 clients, representing approximately 1.5 million distinct providers. Subscription and volume-based revenue together account for 99% of total revenue. Waystar completed its acquisition of Iodine on October 1, 2025, for a total purchase price of $1.26 billion. Its fiscal year ends December 31.
Third Quarter 2026 Results
For the three months ended September 30, 2026, Waystar reported revenue of $325,624 thousand, compared with $268,651 thousand a year earlier. Subscription revenue was $180,726 thousand, compared with $134,450 thousand, and volume-based revenue was $142,860 thousand, compared with $132,342 thousand.
Income from operations was $61,266 thousand, compared with $60,232 thousand. General and administrative expense was $51,393 thousand, compared with $32,422 thousand, and Depreciation and amortization was $41,466 thousand, compared with $33,300 thousand. Net income was $31,025 thousand, or $0.16 per diluted share, compared with $30,648 thousand, or $0.17.
Adjusted EBITDA, a non-GAAP measure, was $139,302 thousand, compared with $112,703 thousand. Non-GAAP net income was $87,150 thousand, or $0.44 per diluted share, compared with $67,795 thousand, or $0.37. The net revenue retention rate for the 12 months ended September 30, 2026 was 107.6%, compared with 113.1%.
Cybersecurity Incident
In early June 2026, Waystar identified the unauthorized acquisition of point-in-time copies of source code from a cloud-based repository hosted by a third-party provider and of four files of inactive data from a single application. The company said the incident was contained and did not involve access to active production systems or client data in active Waystar products. It said the data included protected health information and personally identifiable information associated with fewer than 1% of clients, and that it has no evidence the information has been misused.
Waystar said it believes the incident has not had, and is not reasonably likely to have, a material adverse effect on its operations or financial condition, and that it expects a portion of related costs to be reimbursed through insurance. Incident costs were $1.4 million in the quarter and $3.0 million in the nine months.
Balance Sheet, Cash Flow and Repurchases
At September 30, 2026, cash and cash equivalents were $30,820 thousand and Investment securities were $246,075 thousand. Total outstanding Debt was $1,470,601 thousand, including $1,370,601 thousand on the first Lien term Loan Facility and $100,000 thousand on the receivables facility. Net cash provided by Operating Activities was $248,187 thousand for the nine months, compared with $243,039 thousand. In the third quarter, Waystar repurchased 889,222 shares at an average price of $23.31 per share, and approximately $166.59 million remained available under the plan.
Full-Year 2026 Outlook
On the call, management said it now expects 2026 revenue of $1.277 billion to $1.287 billion and raised its adjusted EBITDA outlook to $543 million to $549 million. It said the revenue outlook implies fourth quarter revenue of approximately $323 million, and cited the shift from printed to digital patient statements, a mix of Iodine activity toward Prebill Anomaly Detection and a prior-year comparison that includes three large client implementations. Management expects 2026 capital expenditures of $55 million to $60 million.






Please wait processing your request...